Abstract:Abstract Purpose: The ACOSOG Z0011 study demonstrated that axillary lymph node dissection (ALND) can be safely omitted in patients with one to two positive sentinel lymph node (SLN) who underwent breast-conserving surgery (BCS) with planned whole-breast irradiation. This study aimed to analysis the surgical management in patients with one to two positive SLNs, and further evaluate the rates of non-sentinel lymph node (non-SLN) metastasis between patients receiving BCS or total mastectomy (TM). Methods: We performed a retrospective analysis of patients with early breast carcinoma from the Shanghai Jiao Tong University-Breast Cancer Database (SJTU-BCDB) between 2011 to 2018. The inclusion criteria were (1) cT1-2N0M0 invasive breast cancer, (2) aged ≥18 years at diagnosis, (3) received surgical treatment for the primary tumor and the axilla, (4) had one to two positive SLNs, (5) no history of previous or concurrent malignant disease, and (6) no neoadjuvant therapy. Patients were classified into the BCS and TM groups. Time trends of ALND rates were analyzed with Chi-square tests. And the rates of non-SLN metastasis between BCS and TM groups were also analyzed with Chi-square tests. Multivariable logistic regression was used to determine factors influencing the completion of ALND and non-SLN metastasis. And Kaplan-Meier estimator and log-rank tests were used to analysis the recurrence-free survival (RFS) between SLNB alone and SLNB+ALND arms. Results: Of the 891 patients enrolled, 586 (65.8%) received TM and 305 (34.2%) received BCS. Between 2011 and 2018, the completion of ALND for 1-2 positive SLN decreased from 100% to 72.7% (P <0.001). And the rate of ALND was significantly higher in the TM group compared with the BCS group (n = 541, 92.3% vs n = 195, 63.9%; P <0.001).Earlier year of diagnosis (P <0.001), primary mastectomy (P <0.001), SLN positive-total ratio >50% (P =0.001), and SLN macro-metastasis (P <0.001) were all independently associated with a higher probability of completing ALND. Among the 736 patients undergone ALND, the rates of non-SLN metastasis were significantly higher in the TM group, compared to the BCS groups (TM: n = 170, 31.4% vs BCS: n = 46, 23.6%; P =0.044). The multivariable regression analysis indicated that non-SLN metastasis was significantly associated with SLN positive-total ratio >50% (OR=3.43, 95%CI 2.28-5.17; P <0.001), Her-2 positive disease (OR=1.63, 95%CI 1.09-2.46; P =0.019), and pT2-3 disease (OR=1.46, 95%CI 1.01-2.09; P =0.042). However, surgery of the breast was not independently associated with the rate of non-SLN metastasis (P =0.090). After a median follow-up time of 31.9 months (range, 1.0-96.5 months), there were no significant difference in RFS between the SLNB alone and SLNB+ALND arms, regardless of the surgery of the breast (TM group: Log-rank P = 0.910; BCS group: Log-rank P =0.840). Conclusion: There is an increasing trend toward omitting ALND in patients with one to two positive SLNs. Compared with the patients undergone BCS, the rate of non-SLN metastasis was significantly higher in patients undergone TM. However, the omission of ALND had limited influence on disease outcome among those patients received TM. Citation Format: Weiqi Gao, Xiaosong Chen, Kunwei Shen. Does the axilla surgical management for limited sentinel lymph nodes involvement vary between total mastectomy and breast-conserving surgery [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS1-53.

Axillary management and long-term oncologic outcomes in breast cancer patients with clinical N1 disease treated with neoadjuvant chemotherapy

De-Escalation of Axillary Surgery in Clinically Node-Positive Breast Cancer Patients Treated with Neoadjuvant Therapy: Comparative Long-Term Outcomes of Sentinel Lymph Node Biopsy versus Axillary Lymph Node Dissection

National Trend of Axillary Management in Clinical T3/T4 N0 Patients Having Breast Conserving Therapy

Axillary Management Following Neoadjuvant Chemotherapy in Clinically Node-Positive Breast Cancer

Impact of axillary surgery on outcome of clinically node positive breast cancer treated with neoadjuvant chemotherapy

Significance of Residual Nodal Disease in Clinically Node-Negative Breast Cancer After Neoadjuvant Chemotherapy

Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla

Management of the axilla with sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer: A single-center study

Omission of Axillary Lymph Node Dissection in Patients with Residual Nodal Disease After Neoadjuvant Chemotherapy

Management of the axilla following neoadjuvant chemotherapy for breast cancer- A change in practice

136P Assessment of Sentinel Lymph Node Biopsy Versus Axillary Lymph Node Dissection on Long-Term Survival in Breast Cancer Patients with Pathologically Negative Lymph Node

Optimal management of breast cancer with physical exam negative/radiological abnormal axilla

Axillary de-escalation after neoadjuvant chemotherapy for advanced lymph node involvement in breast cancer

Long-term survival after sentinel lymph node biopsy or axillary lymph node dissection in pN0 breast cancer patients: a population-based study

Outcomes and Trends in Axillary Management of Stage cN3b Breast Cancer Patients

Impact of Residual Nodal Disease Burden on Sentinel Node Mapping and Accuracy of Intraoperative Frozen Section in Node Positive (cn1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy (NAC)

The Extent of Axillary Surgery is Associated with Breast Cancer-specific Survival in T1-2 Breast Cancer Patients with 1 or 2 Positive Lymph Nodes: A SEER-Population Study.

Axillary lymph node management strategies in cN + breast cancer patients after neoadjuvant chemotherapy

Abstract PS1-53: Does the Axilla Surgical Management for Limited Sentinel Lymph Nodes Involvement Vary Between Total Mastectomy and Breast-Conserving Surgery

Prognostic analysis of cT1-3N1M0 breast cancer patients who have responded to neoadjuvant therapy undergoing various axillary surgery and breast surgery based on propensity score matching and competitive risk model

Axillary Dissection and Nodal Irradiation Can Be Avoided for Most Node-positive Z0011-eligible Breast Cancers: A Prospective Validation Study of 793 Patients